Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis.

The global Midostaurin market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Midostaurin volume and value at global level, regional level and company level. From a global perspective, this report represents overall Midostaurin market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Midostaurin in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Midostaurin manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
AML
MDS
Other

Segment by Application
Hospital
Pharmacy